Benlysta receives Priority Review

FDA accepted for filing and granted Priority Review to a BLA from Human Genome Sciences Inc. (NASDAQ:HGSI) for Benlysta belimumab to treat systemic lupus erythematosus (SLE). The PDUFA date is Dec. 9....